Pulmonary Arterial Hypertension Medication Study

This is a 24-week Phase 2, double-blind study testing the safety of PF-07868489 in patients with Pulmonary Arterial Hypertension (PAH). The primary objective is to evaluate PF-07868489 vs placebo in patients with PAH. The study will evaluate the occurrence of adverse events, change in baseline vital signs and laboratory values, as well as changes in baseline electrocardiogram (ECG) characteristics